Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Marimed (MRMD) Preferred Shares Issued (2017 - 2021)

Marimed has reported Preferred Shares Issued over the past 2 years, most recently at $23.0 million for Q1 2021.

Quarterly Preferred Shares Issued changed N/A to $23.0 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $23.0 million through Dec 2021, changed N/A year-over-year, with the annual reading at $23.0 million for FY2021, N/A changed from the prior year.
Preferred Shares Issued was $23.0 million for Q1 2021 at Marimed, up from $50000.0 in the prior quarter.
Over five years, Preferred Shares Issued peaked at $23.0 million in Q1 2021 and troughed at $50000.0 in Q2 2017.